Bacteria
Bacillus subtilis (Ehrenberg 1835) Cohn 1872
Strain/Type
Bacillus subtilis strain 168
Bacillus subtilis strain DSM10
Host tropism
Route of Transmission
Transmission does not occur.
Zoonosis (transmission between animals and humans): No
Characteristics e.g. sensitizing or toxic effects, resistance to antibiotics
Pathogenicity:
Biological agents that are unlikely to cause human disease.
Note +:
Identified as or suspected of being pathogens in individual cases, mainly in individuals with considerably reduced immunity; identification of the type is often not reliable.
Allergenicity
An allergic / sensitising potential is not known.
B. subtilis produces the extracellular enzyme subtilisin, which has been reported to cause allergic or hypersensitivity reactions in individuals after repeated exposure (e.g. in industrial processes).
Sporulation
Forms spores.
Bacillus subtilis forms heat- and acid-resistant endospores.
Resistances
B. subtilis endospores are highly resistant to harmful environmental factors and common non-sporicidal disinfectants.
Some strains of B. subtilis have been observed to be resistant to different classes of antibiotics.
Approved as biological safety measure if taken as recipient organism for genetic engineering?
Genetically modified (GenTSV)
Risk group (BioStoffV)
1
Risk assessment
Risk accessment based on TRBA (Technical Rule for Biological Agents) 466 "Classification of prokaryotes (bacteria and archaea) into risk groups": https://www.baua.de/DE/Angebote/Rechtstexte-und-Technische-Regeln/Regelwerk/TRBA/TRBA-466.html
Operation instructions (mandatory for RG2 and higher)
https://biostoffe.dguv.de/data?name=820908&lang=en
View file name Bacillus subtillis_Biostoffdokument-820908_en.pdf height 250 View file name Bacillus subtillis_Biostoffdokument-820908.pdf height 250
Occupational health care (according to ArbMedVV)
Optional health care:
In the case of activities with the biological agent no health care is required. An indication on restrictions for immunosuppressed workers should be made.
Vaccination:
Vaccination is not necessary, and a vaccine is not available.
Storage location of aliquots in the Biolab (just click Bearbeiten in the right corner of the header to add or change information in the table and use the menue in the left header to e.g. add a row)
| source | bacterial strain | freezing date | amount of bacteria per vial | stock was produced on | no. of aliquots | belongs to (full name) | rack/box in N2 tank or -80°C freezer and location (room, address) | comments |
|---|---|---|---|---|---|---|---|---|
Beuth Hochschule für Technik Berlin Daniela Wischer FB V, BT, Mikrobiologie Seestraße 64 13347 Berlin Germany | Bacillus subtilis strain 168 | 19.09.2019 | 1 ml | 19.09.2019 | 15 | Elisa Quaas | -80°C "Omega", Shelf B, Rack 1, Box 5, Room 115.2, SupraFAB, Altensteinstraße 23a | |
| Christan Roth, AG Seeberger, Arnimallee 22, 14195 Berlin | Bacillus subtilis strain DSM10 | 21.02.2023 | 500 µl | 21.02.2023 | 18 | Elisa Quaas | -80°C "Omega", Shelf B, Rack 1, Box 5, Room 115.2, SupraFAB, Altensteinstraße 23a | |
| Mingjun Li | 1ml | LB | 10 | Chuanxiong Nie | -80°C "Π", A-5-31 | |||
Background
Cultivation and freezing protocols
Data sheets, further information
View file name Bacillus-subtilis_DSM10_German Collection of Microorganisms and Cell Cultures GmbH Details.pdf height 250
